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Neuropathic pain in AIDS patients prior to antiretroviral 
therapy
S A Hitchcock, H P Meyer, E Gwyther
The human immunodeficiency virus (HIV) has a predilection 
for nerve tissue; therefore, the peripheral nerves, spinal cord 
and brain are frequently affected in patients with HIV/AIDS, 
resulting in a high prevalence of neuropathic pain. Neuropathic 
pain is defined by the International Association for the Study of 
Pain (IASP) as ‘… pain initiated or caused by a primary lesion 
or dysfunction of the nervous system’.1 The lesion may occur 
anywhere within the central or peripheral nervous system and 
may lead to structural and functional changes in the nervous 
system, resulting in altered central neural processing of sensory 
input (central sensitisation). Consequently, pain may persist 
long after healing of the original injury. Neuropathic pain may 
therefore be regarded as abnormal activation of pain pathways.
Neuropathic pain syndromes typically present with both 
negative and positive sensory symptoms and signs. The usual 
qualities of neuropathic pain are burning, pricking, shooting or 
aching. This may be accompanied by hyperalgesia, allodynia, 
dysaesthesia or paraesthesiae. Neuropathic pain is not 
necessarily an all-or-nothing phenomenon but may be part of a 
spectrum where the pain is ‘more or less neuropathic’ in origin, 
hence the concept of pain of predominantly neuropathic origin 
(POPNO).2,3
Several instruments, specifically designed for the 
identification of neuropathic pain, were reviewed. The 
Neuropathic Pain Diagnostic Questionnaire (DN4), developed 
by the French Neuropathic Pain Group, was selected for use in 
this study, because of its brevity and simple application. It has 
been validated in a single study and found to have a sensitivity 
of 82.9% and specificity of 89.9% for identifying neuropathic 
pain.4
The most frequent cause of neuropathic pain in patients 
with HIV infection is a distal sensory polyneuropathy (DSP), 
which may either be the result of the HIV infection itself or of 
neurotoxicity from drugs used in treating patients with AIDS. 
The combined effect of the potentially neurotoxic antiretroviral 
drugs, d4T and ddI, with isoniazid used in the treatment of 
tuberculosis, may cause significant problems. Malignancies, 
central neuropathic pain secondary to cerebrovascular 
incidents, herpes zoster and post-herpetic neuralgia are 
additional causes of neuropathic pain in HIV-infected patients.
There is limited evidence in the literature regarding the 
prevalence of neuropathic pain in AIDS patients. Several 
studies have investigated the prevalence of symptomatic DSP 
in AIDS patients, which ranges from 35% to 45%.5,6
The prevalence of neuropathic pain in AIDS patients in 
South Africa is unknown, and little is known about its severity 
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Objective. To measure the prevalence, severity and morbidity 
of neuropathic pain in AIDS patients, prior to the initiation of 
antiretroviral (ARV) therapy.
Design. A prospective, cross-sectional and descriptive-
analytical study.
Setting. The Kalafong Hospital HIV Clinic in Pretoria.
Subjects. All patients with confirmed AIDS who were referred 
to the Kalafong HIV clinic to be initiated on ARV therapy 
during the period August 2006 to March 2007.
Outcome measures. Data were collected regarding the presence 
and severity of neuropathic pain in each subject. Pain of 
predominantly neuropathic origin (POPNO) was identified 
using the Neuropathic Pain Diagnostic Questionnaire (DN4). 
Numerical rating scales (NRS), adapted from the Brief Pain 
Inventory, were used to measure pain severity and pain-
related interference with six aspects of daily living.
Results. Of the 354 patients studied, 20.9% (95% confidence 
interval (CI) 16.8 - 25.2%) had POPNO. This pain was 
significantly more frequent in patients who were male, had 
lower CD4+ counts or higher viral load levels, and those 
on TB treatment. Eighty per cent of patients with POPNO 
experienced significant pain (worst pain severity ≥5 out 
of 10 on a NRS). Pain-related interference was highest for 
enjoyment of life, mood and ability to work. There was a 
significant positive correlation between severity of pain 
and pain-related interference for all domains of daily living 
evaluated.
Conclusions. POPNO results in significant suffering and 
impaired functioning in patients with AIDS. It is therefore 
imperative that clinicians assess patients with AIDS for the 
presence and severity of neuropathic pain and manage it, 
using the most recent evidence-based guidelines.
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or impact on their lives. Although neuropathic pain in AIDS 
patients is common, it is frequently under-diagnosed and 
under-treated, and a lack of awareness of the extent of the 
problem could contribute to the inadequate management.7 
Failure to recognise when neuropathic pain mechanisms 
predominate and the lack of knowledge of appropriate 
treatment, results in failure to treat patients appropriately.
Our aim was to identify the prevalence, severity and effects 
on quality of life by pain that is predominantly neuropathic 
in origin in patients with AIDS, prior to the initiation of ARV 
therapy.
Methods
Study setting and population
A prospective survey of new patients referred to the Kalafong 
Hospital HIV Clinic in Pretoria was conducted from August 
2006 to March 2007. Only patients with confirmed AIDS and 
who require ARV therapy are referred to this clinic. Each new 
patient was invited to participate in the study. All subjects met 
the 1993 Centers for Disease Control (CDC) case definition 
criteria for AIDS, namely a history of an AIDS-defining 
clinical condition or a CD4 lymphocyte count <200 cells/µl.8 
Patients already using ARV medication, or who had cognitive 
impairment such that they would be unable to answer the 
questionnaire, were excluded. The study was approved by the 
Research and Ethics Committees of the Universities of Cape 
Town and Pretoria. Patients were included only after they had 
given informed, written consent.
Data collection
Data were collected using an interviewer-administered 
questionnaire and focused neurological examination (Table I).
Analysis of data
Data were analysed using SPSS for Windows statistical 
software. Descriptive statistics were produced to examine 
the study sample, prevalence and severity of POPNO and 
pain-related interference. Means ± standard deviations were 
used for continuous variables, and frequency distributions for 
categorical variables. Factors associated with the presence of 
POPNO were identified using chi-squared tests. Kruskal-Wallis 
statistics were used to evaluate significant linear relationships 
between the severity of POPNO and interference items. 
Statistical significance was evaluated at the 95% confidence 
level.
Results
This study included 354 patients diagnosed with AIDS, with 
a mean age of 36.3 years (±8.6) and ranging from 18 to 67 
years. Female patients (mean age 35.0 years) were significantly 
younger than male patients (mean age 40.0 years) (p<0.001). 
Patients had a mean CD4+ count of 111 (±70.8). Of the 
sample, 21% had recently received or were currently receiving 
tuberculosis treatment.
The distribution of pain within the whole sample (N=354) 
is displayed in Fig. 1. The prevalence of significant pain of 
any type within the whole sample was 62.1% (220 patients). 
Male patients experienced significantly more pain, with 72.9% 
having pain, compared with 58.1% of female patients (p=0.011).
Of the total sample, 20.9% (74 patients) (95% CI 16.8 - 25.2%) 
had POPNO, based on achieving a score of four or more (range 
0 - 10), using the DN4. Chi-squared analysis demonstrated a 
significantly higher prevalence of POPNO in male patients 
(31.3%), compared with 17.1% in female patients (p=0.003). 
Patients with lower CD4+ counts (p=0.009) and those with 
higher viral load values (p=0.006) showed a significantly higher 
prevalence of POPNO, as did patients with a history of recent 
or current treatment for tuberculosis (p<0.001). The POPNO 
was located in the lower limbs in 84% (62 out of 74) patients. 
It is therefore likely that most of the neuropathic pain in this 
study was as a result of a peripheral neuropathy.
Fig. 1. Distribution of pain (N=354).
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Fig. 1. Distribution of pain (N=354).
Table I. Questionnaire and neurological examination
All patients
•    Basic demographic details, CD4+ count, viral load and use of 
tuberculosis treatment.
•    The question was asked, ‘Have you experienced pain that 
has troubled you a lot in the past two weeks?’ Patients who 
answered in the affirmative were classified as having pain of 
any type.
Patients with pain of any type
•    Pain location on a body map drawing.
•    Neuropathic Pain Diagnostic Questionnaire (DN4) 
administered to identify patients with POPNO.
POPNO patients
•    Measurement of worst and average pain severity using a 
numerical rating scale (NRS).
•    Measurement of pain-related interference with daily 
functioning, using NRS, adapted from the Brief Pain 
Inventory (BPI).
•    Focused neurological examination, including touch and 
pain sense and mechanical and thermal allodynia. Vibration 
sense, deep tendon reflexes and muscle power were tested in 
patients where POPNO was located in a limb.
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Regarding the severity of POPNO, a numerical rating scale 
(NRS) score for worst pain of 1 - 4 was regarded as mild pain 
(20.3% of patients), NRS 5 - 7 as moderate pain (39.2%), and 
NRS 8 - 10 as severe pain (40.5%). The mean score for pain at 
its worst was 6.31 (±2.57).
Pain-related interference was measured for 6 aspects of daily 
functioning. The domains of ‘enjoyment of life’, ‘mood’ and 
‘ability to work’ were most affected by the neuropathic pain. 
At least 25% of the POPNO patients experienced severe pain-
related interference in these three aspects of functioning. In 
addition, sleep and walking were found to be severely affected 
by the pain in 23% and 17.6% of patients, respectively. A 
significant positive correlation was demonstrated between pain 
severity and pain-related interference (Fig. 2).
Of the 74 patients with POPNO, 91.9% displayed at least 1 
or more clinical abnormalities on neurological examination, the 
most frequent being abnormal pinprick sense (73% of patients), 
abnormal tactile sense (68.9%) and decreased or absent 
vibration sense (62.1%). Hypoaesthesia for pinprick and tactile 
sense occurred more commonly than hyperaesthesia.
Discussion
This study’s POPNO prevalence of 20.9% is lower than 
expected in comparison with previous studies in Africa and 
the USA, where a prevalence of symptomatic DSP in AIDS 
patients of 35 - 45% was found.5,6 The higher prevalence of 
POPNO found in male patients, those with a lower CD4 
cell count and a higher viral load, and those on tuberculosis 
treatment, confirms previous findings, where lower CD4+ 
counts and male gender were significantly associated with a 
higher prevalence of polyneuropathy.9 This correlation implies 
that the timely use of ARV therapy could lower the incidence 
of neuropathic pain in this population.
An objective of this study was to increase awareness among 
clinicians of the severity and impact of neuropathic pain in 
AIDS patients. This and previous pain studies on HIV patients 
describe ‘worst pain’ (rated as 5 or above) as significant pain, 
and report it as contributing to disproportionately more 
functional impairment.7,10 In this study, 79.7% of POPNO 
patients rated their worst pain as 5 or more, which is higher 
than a USA study of patients with metastatic cancer.10 It has 
been shown3 that the general health status measure (SF-36) of 
patients with POPNO was comparable with that of patients 
with serious somatic diseases, including coronary artery 
disease, recent myocardial infarction and poorly controlled 
diabetes.11
The burden carried by patients as a result of POPNO may be 
more accurately understood by measurement of impairment 
of function and reduced quality of life. The pain-related 
interference ratings in this study are similar to those in a USA 
study of post-herpetic neuralgia in older persons.12 Controlling 
POPNO has the potential to greatly improve functioning and 
quality of life; however, analgesic and adjuvant drug side-
effects must be taken into account.
It is significant that 91.9% of patients with POPNO 
demonstrated an objective clinical abnormality, of which 
decreased tactile, pinprick and vibration sense were the most 
common. A focused neurological examination which includes 
these modalities may therefore be of particular value in AIDS 
patients with suspected neuropathic pain.
Limitations of study
Representation was limited to patients with AIDS who were 
willing and able to attend this public health facility for ARV 
therapy. It excluded those who were unable or unwilling to use 
ARV therapy or unable to attend due to physical disabilities 
and/or socio-economic factors. These factors could have 
resulted in a disproportionate number of patients who were 
most affected by AIDS having been excluded. Furthermore, 
the sample was restricted to patients reliant on public health 
care and patients not yet using ARV therapy. Further research 
should be done, involving more varied populations and 
patients on ARV therapy. It would be of value to determine 
the influence of ARV therapy – in particular, the widely used 
nucleoside reverse transcriptase inhibitors (NRTIs) – on the 
prevalence of neuropathic pain in AIDS patients.
Conclusions and recommendations
This study demonstrates a significant prevalence and impact 
of neuropathic pain in patients with AIDS. These findings 
underscore the need for improved pain control in AIDS 
patients to improve their quality of life and assist them in 
remaining economically active. While the timely use of ARV 
therapy can contribute to the management of AIDS-related 
neuropathic pain, additional measures are frequently required. 
These include appropriate assessment of pain with regard 
to the type, severity and related functional impairment and 
appropriate pain management, alongside ARV therapy.
In contrast to pain management in general, neuropathic 
pain requires a more rigorous approach, involving a 
multidimensional bio-psycho-social approach that involves 
Fig. 2. Correlation between severity of POPNO and overall pain-related interference score
(N=74, p<0.001 (Kruskal-Wallis)).
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 Fig. 2. Correlation between severity of POPNO and overall pain-related 
interference score (N=74, p<0.001 (Kruskal-Wallis)).
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the use of appropriate pharmacological agents, exercise, 
behavioural therapy, attention to sleep quality, patient 
education and return to work if possible.13 Pharmacological 
management places particular emphasis on adjuvant drugs, 
added to non-opioid and opioid analgesics. Clinicians should 
avail themselves of current evidence regarding the most 
effective adjuvant drugs for neuropathic pain, with the fewest 
side-effects. Several classes of adjuvant drugs have proven 
efficacy in neuropathic pain, although further studies are 
required to prove their efficacy specifically in HIV-related 
neuropathic pain. These include the tricyclic antidepressants 
(TCAs), anticonvulsants (in particular the α2-δ ligands, such 
as gabapentin and pregabalin) and the newer serotonin and 
noradrenaline re-uptake inhibitors (SNRIs).14
In South Africa, primary health care providers are in the 
most favourable position to assess and manage patients 
presenting with POPNO, utilising a multidisciplinary 
approach, and have a responsibility to develop the required 
knowledge and skills. Patients with complicated presentations 
and those who do not respond to a first-line approach should 
be referred to appropriate specialists.13 Given the extent of the 
problem of AIDS in South Africa, a patient-centred approach 
is imperative to alleviate suffering and improve the lives of 
patients with AIDS and neuropathic pain.
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